Ligand validation:3ZNK

NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose

NAG is a Ligand Of Interest in 3ZNK designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
3ZNK_NAG_C_1023	66%	57%	0.134	0.938	0.56	1.06	-	1	1	0	100%	0.9333
3ZNK_NAG_E_1023	61%	58%	0.136	0.924	0.5	1.1	-	1	1	0	100%	0.9333
3ZNK_NAG_A_1023	57%	58%	0.151	0.927	0.51	1.07	-	1	1	0	100%	0.9333
3ZNK_NAG_A_1165	44%	44%	0.165	0.892	0.75	1.38	-	2	0	1	100%	0.9333
3ZNK_NAG_D_1154	41%	53%	0.175	0.891	0.56	1.24	-	1	0	1	100%	0.9333
3ZNK_NAG_E_1165	35%	43%	0.168	0.854	0.77	1.43	-	2	0	0	100%	0.9333
3ZNK_NAG_C_1165	32%	47%	0.19	0.862	0.69	1.33	-	1	1	0	100%	0.9333
3ZNK_NAG_F_1154	24%	48%	0.206	0.834	0.44	1.53	-	1	0	1	100%	0.9333
3ZNK_NAG_B_1154	22%	55%	0.232	0.849	0.57	1.15	-	1	0	1	100%	0.9333
4CR0_NAG_A_1165	83%	51%	0.112	0.97	0.49	1.37	-	1	0	0	100%	0.9333
4KDQ_NAG_E_502	81%	59%	0.104	0.957	0.53	1.02	-	2	2	0	100%	0.9333
4BH0_NAG_E_1320	80%	62%	0.091	0.938	0.39	1.06	-	1	0	0	100%	0.9333
4K64_NAG_A_601	70%	61%	0.125	0.942	0.51	0.97	-	1	0	0	100%	0.9333
4CQZ_NAG_A_1327	68%	57%	0.112	0.922	0.46	1.16	-	2	0	0	100%	0.9333
1OC7_NAG_A_500	100%	60%	0.04	0.991	0.61	0.9	-	1	0	0	100%	0.9333
1OC6_NAG_A_500	100%	67%	0.041	0.988	0.46	0.8	-	1	0	0	100%	0.9333
1UWC_NAG_A_262	100%	54%	0.046	0.99	0.83	0.93	-	-	0	0	100%	0.9333
6ZE6_NAG_B_703	100%	52%	0.044	0.984	0.78	1.07	-	2	0	0	100%	0.8667
6ZE2_NAG_B_704	99%	56%	0.042	0.979	0.73	0.95	-	1	0	0	100%	0.9333

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.